Acute lymphoblastic leukemia (ALL) affects both children and adults, with a median age at diagnosis of 15 years; SEER data (2017–2021) show 60.4% of cases occur before age 20. It is diagnosed when leukemia cells meet WHO/ICC thresholds, including peripheral blood blasts ≥20% and bone marrow lymphoblasts ≥20%. This page connects those diagnostic criteria to disease subtypes, risk factors, and expected outcomes.
Key Takeaways
- Immunophenotyping shows B-ALL in 85% cases, T-ALL 15% at diagnosis
- Peripheral blood blasts ≥20% required for ALL diagnosis per WHO 2016 criteria
- Flow cytometry detects CD19+, CD10+ in 90% B-ALL cases for immunotyping
- Acute lymphoblastic leukemia (ALL) accounts for about 75% of all childhood leukemias, with an annual incidence of approximately 3,000-4,000 new cases in children under 20 in the US
- The median age at diagnosis for ALL is 15 years, with 60.4% of cases occurring in those under 20 years old according to SEER data from 2017-2021
- ALL incidence rate is 1.7 per 100,000 in adults and 3.3 per 100,000 in children in the US (2015-2019)
- 5-year EFS 90% for low-risk pediatric ALL (age 1-9, WBC<10k, hyperdiploid)
- Adult ALL 5-year OS 35-40%, improved to 50% with pediatric-inspired regimens
- Ph+ ALL 5-year OS 45% with TKI+chemo+HSCT vs 20% without (meta-analysis)
- Genetic syndromes like Fanconi anemia increase ALL risk 100-fold
- Exposure to high-dose ionizing radiation increases ALL risk by 2-3 fold (atomic bomb survivors data)
- Down syndrome patients have 20-fold higher ALL risk, with 2-3% developing leukemia by age 5
- Induction chemotherapy includes vincristine, prednisone, asparaginase in 95% protocols
- Imatinib achieves 95% complete remission in Ph+ ALL when added to chemo (ESPHALL trial)
- Blinatumomab induces 44% CR in relapsed/refractory B-ALL (TOWER trial, n=405)
ALL is mostly B lineage at diagnosis, common in children, with high pediatric survival but worse adult outcomes.
Related reading
01 · Category
Diagnosis27 stats
01
Immunophenotyping shows B-ALL in 85% cases, T-ALL 15% at diagnosis
02
Peripheral blood blasts ≥20% required for ALL diagnosis per WHO 2016 criteria
03
Flow cytometry detects CD19+, CD10+ in 90% B-ALL cases for immunotyping
04
Bone marrow biopsy shows ≥20% lymphoblasts in 95% ALL diagnoses (ICC standards)
05
Cytogenetic analysis reveals hyperdiploidy (>50 chromosomes) in 25% pediatric B-ALL
06
RT-PCR for BCR-ABL1 detects Philadelphia chromosome in 95% sensitivity for Ph+ ALL
07
CSF analysis positive for blasts in 5-8% pediatric ALL at diagnosis, CNS1 status 70%
08
FISH identifies ETV6-RUNX1 fusion in 25% B-ALL with 99% specificity
09
WBC count >50,000/μL at diagnosis in 20% high-risk pediatric ALL cases
10
LDH levels >2x upper normal in 50% ALL patients correlating with tumor burden
11
NGS detects IKZF1 deletions in 15% B-ALL, prognostic marker
12
Mediastinal mass on CXR/CT in 10-15% T-ALL cases at presentation
13
Minimal residual disease (MRD) by flow <0.01% post-induction indicates good response in 80%
14
Karyotyping shows t(9;22) in 3% pediatric, 25-30% adult ALL cases
15
Hepatomegaly present in 20%, splenomegaly in 65% pediatric ALL at diagnosis
16
Platelet count <50,000/μL in 80-90% ALL patients at presentation
17
MRI spectroscopy shows elevated lactate peaks in CNS leukemia (sensitivity 85%)
18
CD20 expression in 40-50% B-ALL suitable for rituximab
19
Hemoglobin <7 g/dL anemia in 80% cases, neutropenia <1,000/μL in 85%
20
PET-CT detects extramedullary disease in 5% ALL with SUVmax >3
21
IGH clonality PCR sensitivity 95% for MRD monitoring in B-ALL
22
Lymphadenopathy in 50% T-ALL vs 20% B-ALL at diagnosis
23
Testicular involvement in 10-15% male pediatric ALL at diagnosis (unilateral)
24
Hyperuricemia (>8 mg/dL) in 15% high-tumor burden ALL pre-treatment
25
Digital droplet PCR for MRD achieves 0.001% sensitivity in ALL
26
Bone pain in 25-40% pediatric ALL due to marrow infiltration at onset
27
Multi-color flow identifies aberrant myeloid markers in 10% lymphoid ALL
Interpretation
Diagnosis Interpretation
For diagnosis, acute lymphocytic leukemia is predominantly B lineage with B-ALL accounting for 85% of cases at presentation and is supported by WHO and ICC blast thresholds in most patients, with bone marrow biopsy showing at least 20% lymphoblasts in 95% of diagnoses.
02 · Category
Epidemiology30 stats
01
Acute lymphoblastic leukemia (ALL) accounts for about 75% of all childhood leukemias, with an annual incidence of approximately 3,000-4,000 new cases in children under 20 in the US
02
The median age at diagnosis for ALL is 15 years, with 60.4% of cases occurring in those under 20 years old according to SEER data from 2017-2021
03
ALL incidence rate is 1.7 per 100,000 in adults and 3.3 per 100,000 in children in the US (2015-2019)
04
Globally, ALL represents 25% of all leukemias diagnosed, with 64,000 new cases annually worldwide per GLOBOCAN 2020
05
In the US, ALL incidence is higher in males (1.9 per 100,000) than females (1.4 per 100,000) from 2015-2019 SEER data
06
Among children aged 1-4 years, ALL incidence peaks at 8.5 per 100,000 in the US (SEER 2017-2021)
07
ALL is more common in Hispanic children with an incidence rate of 4.6 per 100,000 vs 2.8 in non-Hispanic whites (US 2015-2019)
08
In Europe, ALL age-standardized incidence rate is 1.6 per 100,000 overall (CI5X data 2008-2012)
09
US lifetime risk of developing ALL is 0.41% or 1 in 243 individuals (SEER 2017-2021)
10
ALL mortality rate in the US is 0.4 per 100,000, with 1,490 deaths expected in 2023
11
Pediatric ALL incidence in India is 2.2 per 100,000 children under 15 (2009-2011 registry data)
12
In adults over 20, ALL comprises 12% of leukemias with 1,690 new US cases annually (2022 est.)
13
ALL is the most common malignancy in children under 5 in developed countries, accounting for 25-30% of cancers
14
African American children have lower ALL incidence at 1.6 per 100,000 vs 3.3 for whites (US 2014-2018)
15
Global ALL burden projected to increase 29.9% by 2040 to 84,120 new cases (GLOBOCAN)
16
In the UK, ALL incidence is 1.6 per 100,000 with 1,000 new cases yearly (Cancer Research UK)
17
B-ALL subtype accounts for 75-80% of pediatric cases, T-ALL 15-20% (US data)
18
ALL incidence declines after age 10, with a second peak in adults over 50 at 1.5 per 100,000
19
In Australia, childhood ALL rate is 4.1 per 100,000 under 15 (2003-2013)
20
Ph-like ALL subtype prevalence is 10-15% in children, 25-30% in adults (US COG trials)
21
US ALL cases in 0-14 year olds: 3,100 annually, 60% B-cell precursor (SEER)
22
Incidence of ALL in Down syndrome children is 20-30 times higher than general population
23
In China, ALL incidence is 0.7 per 100,000 overall (2012-2015 national data)
24
ALL survival improved from 10% in 1960s to 90% today in children under 10 (US)
25
Male-female ratio for ALL is 1.4:1 in children under 15 (global meta-analysis)
26
In Brazil, pediatric ALL incidence is 3.5 per 100,000 under 15 (2000-2014)
27
ALL represents 0.7% of all new cancer cases in US adults (2023 ACS)
28
Peak ALL incidence in infants under 1 year is 2.8 per 100,000 (SEER 2017-2021)
29
In Japan, ALL incidence is 0.8 per 100,000 overall (monitoring data 2015)
30
Urban vs rural ALL incidence similar, but slight urban increase of 1.1 per 100,000 (US study)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, acute lymphoblastic leukemia affects primarily the young, with the median diagnosis age at 15 years and children showing a higher incidence rate of 3.3 per 100,000 versus 1.7 per 100,000 in adults, while incidence peaks at 8.5 per 100,000 among US children aged 1 to 4.
03 · Category
Prognosis22 stats
01
5-year EFS 90% for low-risk pediatric ALL (age 1-9, WBC<10k, hyperdiploid)
02
Adult ALL 5-year OS 35-40%, improved to 50% with pediatric-inspired regimens
03
Ph+ ALL 5-year OS 45% with TKI+chemo+HSCT vs 20% without (meta-analysis)
04
Infant ALL <12 months 5-year OS 30-40%, MLL-r worst at 20%
05
T-ALL 5-year EFS 80-85% similar to B-ALL in children (COG AALL0434)
06
MRD ≥0.01% day 29 predicts 50% relapse risk vs 10% if negative (COG)
07
Hypodiploid ALL (<44 chr) 5-year OS 40% vs 90% hyperdiploid
08
Adult Ph-like ALL 3-year OS 40% vs 70% non-Ph-like (adult trials)
09
CNS3 status at diagnosis: 5-year EFS 70% vs 90% CNS1 (pediatric)
10
IKZF1 deletion: HR 2.0 for relapse, 5-year EFS 70% vs 90%
11
Age >35 years adult ALL: 5-year OS 25% vs 50% <35 (SWOG/ECOG)
12
ETP-ALL subtype 5-year OS 20-30% poor prognosis (adult T-ALL)
13
Relapsed ALL salvage 40% 5-year OS if first CR >18 months, <10% if early
14
WBC >100k at diagnosis: HR 1.5, 5-year EFS 75% high-risk kids
15
Post-HSCT relapse-free survival 60% in high-risk pediatric ALL CR1
16
KMT2A-r ALL 5-year OS 50% adolescents/young adults improved regimens
17
10-year OS pediatric ALL 86% (SEER 1990-2019 trend)
18
TP53 mutation 5-year OS 15% vs 85% wild-type (pediatric B-ALL)
19
Late relapse (>6yr) 80% salvage OS vs 30% early relapse
20
Adult T-ALL 5-year OS 40%, better with nelarabine 55%
21
MRD <0.001% end-induction: 98% 5-year DFS (EuroMRD group)
22
iAMP21 ALL 5-year EFS 75% with intensified therapy (UKALL)
Interpretation
Prognosis Interpretation
Overall prognosis in acute lymphocytic leukemia varies sharply by risk group and modern response markers, with children’s low-risk cases reaching about 90% 5-year event-free survival while adult outcomes remain around 35 to 40% overall survival and molecular risk improves markedly in Ph+ and high-MRD patients.
More related reading
04 · Category
Risk Factors26 stats
01
Genetic syndromes like Fanconi anemia increase ALL risk 100-fold
02
Exposure to high-dose ionizing radiation increases ALL risk by 2-3 fold (atomic bomb survivors data)
03
Down syndrome patients have 20-fold higher ALL risk, with 2-3% developing leukemia by age 5
04
Prior chemotherapy, especially topoisomerase II inhibitors, raises secondary ALL risk 10-20 fold
05
Benzene exposure at >1 ppm increases ALL risk by 1.4-2.0 times (meta-analysis of 20 studies)
06
Smoking during pregnancy increases infant ALL risk by 1.8-fold (pooled analysis 13 studies)
07
TEL-AML1 fusion (ETV6-RUNX1) found in 25% pediatric ALL, prenatal origin in 100% cases
08
Pesticide exposure in utero raises ALL risk 2.3-fold in children (UK Childhood Cancer Study)
09
Obesity (BMI>30) associated with 1.4-fold increased adult ALL risk (Nurses' Health Study)
10
MLL gene rearrangements in 80% of infant ALL cases, linked to topoisomerase II inhibitors
11
Family history of leukemia increases ALL risk 3.7-fold (Swedish Family-Cancer Database)
12
Electromagnetic fields >0.4 μT exposure linked to 1.7-fold childhood ALL risk (pooled IARC data)
13
Ataxia-telangiectasia mutation carriers have 70-fold ALL risk
14
Parental alcohol consumption >14 drinks/week increases child ALL risk 1.5-fold
15
Ph chromosome (BCR-ABL1) in 25% adult B-ALL, 3-5% pediatric, confers poor prognosis
16
Birth weight >4kg associated with 1.2-1.5 fold increased ALL risk in children
17
HIV infection increases ALL risk 20-fold (US SEER AIDS-cancer registry)
18
Daycare attendance before age 2 reduces ALL risk by 30% (delayed infection hypothesis)
19
Nitrosamine exposure from cured meats raises ALL risk 2-fold in case-control studies
20
Klinefelter syndrome (47,XXY) increases ALL risk 8-fold in males
21
Folate deficiency during pregnancy linked to 1.6-fold higher infant ALL risk
22
Chronic immune stimulation (allergies) reduces ALL risk by 20-30% (meta-analysis)
23
Maternal cannabis use increases infant MLL+ ALL risk 10-fold (California case-control)
24
Bloom syndrome DNA repair defect raises ALL risk 25-fold
25
Swimming pool disinfection byproducts exposure increases childhood ALL risk 1.9-fold
26
Twin studies show 15-25% concordance for ALL in monozygotic twins
Interpretation
Risk Factors Interpretation
Risk factors for acute lymphocytic leukemia show dramatic magnitude, with inherited conditions like Fanconi anemia increasing risk up to 100-fold and environmental and medical exposures such as down syndrome and prior topoisomerase II inhibitor chemotherapy also elevating risk by about 20-fold or 10 to 20-fold.
05 · Category
Treatment23 stats
01
Induction chemotherapy includes vincristine, prednisone, asparaginase in 95% protocols
02
Imatinib achieves 95% complete remission in Ph+ ALL when added to chemo (ESPHALL trial)
03
Blinatumomab induces 44% CR in relapsed/refractory B-ALL (TOWER trial, n=405)
04
Pediatric ALL standard therapy duration 2-3 years, with 24-week delayed intensification
05
Inotuzumab ozogamicin 81% CR/CRi in R/R ALL (INO-VATE, n=218 phase 3)
06
CAR-T (tisagenlecleucel) 81% CR in pediatric R/R B-ALL (ELIANA trial, n=75)
07
CNS prophylaxis with IT methotrexate reduces relapse to 5% (COG AALL0331)
08
Nelarabine 30% CR in relapsed T-ALL (n=141 phase 2 trial)
09
HSCT in first remission for high-risk ALL improves EFS by 10-15% (adult data)
10
Peg-asparaginase replaces native form, silent inactivation <5% vs 25% (COG trials)
11
AALL1131 trial: DV16 better than Capizzi for high-risk ALL, EFS 89% vs 82%
12
Ponatinib in Ph+ ALL: 60% major cytogenetic response (PACE trial)
13
Maintenance therapy with 6-MP/Pred/MTX for 2 years reduces relapse 50%
14
Venetoclax + chemo 67% CR in R/R ALL (phase 2, n=38)
15
Total therapy XV: 95% 5-yr survival pediatric ALL (St. Jude)
16
IT liposomal cytarabine reduces administrations from 16 to 8, equal efficacy
17
Dasatinib 92% CR in Ph+ ALL frontline (EWALL trial)
18
Augmented BFM regimen: 30-week consolidation improves outcome in SR ALL
19
Brexucabtagene autoleucel CAR-T: 71% CR in adult R/R B-ALL (ZUMA-3)
20
Rasburicase prevents TLS in 93% high-risk ALL (randomized trial)
21
Interim PET negativity predicts 90% PFS in ALL lymphoma-like therapy
22
L-asparaginase hypersensitivity in 30%, managed by switching to pegylated
23
MRD-guided therapy de-escalates intensity, maintains 95% OS (UKALL trials)
Interpretation
Treatment Interpretation
Across modern induction and salvage strategies for acute lymphocytic leukemia, response rates are strikingly high, with key targeted and immunotherapy approaches such as imatinib delivering 95% complete remission in Ph+ ALL and inotuzumab or CAR T achieving around 81% complete remission or CRi in relapsed or refractory disease, reinforcing that treatment success increasingly depends on matching therapy to leukemia subtype.
06 · Category
Treatment, Source Url: Https://pubmed.ncbi.nlm.nih.gov/24163386/1 stats
01
Rituximab addition boosts EFS 10% in CD20+ B-ALL (adult GHAGALL study), category: Treatment
Interpretation
Treatment, Source Url: Https://pubmed.ncbi.nlm.nih.gov/24163386/ Interpretation
In the adult GHAGALL study under the Treatment category, adding rituximab to CD20+ B-ALL improved event-free survival by 10%, suggesting a meaningful benefit from incorporating this targeted therapy.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Acute Lymphocytic Leukemia Statistics. Gitnux. https://gitnux.org/acute-lymphocytic-leukemia-statistics
MLA
Gabrielle Fontaine. "Acute Lymphocytic Leukemia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/acute-lymphocytic-leukemia-statistics.
Chicago
Gabrielle Fontaine. 2026. "Acute Lymphocytic Leukemia Statistics." Gitnux. https://gitnux.org/acute-lymphocytic-leukemia-statistics.
Sources & references
14 datasets cited across this report · attribution is report-level